Last reviewed · How we verify
Rescue Intravitreal Aflibercept Injection
Aflibercept is a recombinant fusion protein that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the retina.
Aflibercept is a recombinant fusion protein that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the retina. Used for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion.
At a glance
| Generic name | Rescue Intravitreal Aflibercept Injection |
|---|---|
| Sponsor | Southeast Retina Center, Georgia |
| Drug class | VEGF inhibitor / Recombinant fusion protein |
| Target | VEGF-A, VEGF-B, PlGF (placental growth factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Aflibercept acts as a soluble decoy receptor that traps VEGF-A, VEGF-B, and PlGF in the vitreous, preventing these growth factors from activating their endogenous receptors on retinal vascular endothelial cells. By blocking VEGF signaling, it reduces pathological neovascularization and vascular permeability in retinal diseases. This mechanism stabilizes or improves vision in conditions characterized by abnormal retinal angiogenesis and edema.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Diabetic macular edema
- Retinal vein occlusion
- Diabetic retinopathy
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
Key clinical trials
- Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E (PHASE4)
- Aflibercept in Polypoidal Choroidal Vasculopathy (PHASE4)
- Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy (PHASE4)
- Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO) (PHASE3)
- Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: